1. Home
  2. GERN

GERN

Geron Corporation

Logo Geron Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Founded: 1990 Country:
United States
United States
Employees: 141 City: FOSTER CITY
Market Cap: 2.2B IPO Year: 1996
Target Price: $5.33 AVG Volume (30 days): 12.2M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.32 EPS Growth: N/A
52 Week Low/High: $1.64 - $4.05 Next Earning Date: 05-09-2024
Revenue: $237,000 Revenue Growth: -60.23%
Revenue Growth (this year): 27485.23% Revenue Growth (next year): 345.19%

Share on Social Networks: